Studies of NAD+ and sirtuins measure molecule levels, enzyme activity, protein changes, and whole-body outcomes.

Studies of NAD+ and sirtuins measure molecule levels, enzyme activity, protein changes, and whole-body outcomes. Human studies of NR and NMN have reported increases in blood NAD-related markers, but functional results are less consistent; neither kind of result by itself establishes slower aging. NAD+ is a coenzyme, not a peptide; research peptide studies may examine related cell pathways, but the materials are distinct.

NAD+ is a coenzyme, a molecule that helps other molecules carry out chemical reactions. It also acts as a helper molecule in sirtuin reactions, linking cell energy use with changes to proteins.
Sirtuins are a family of seven enzymes, proteins that speed chemical reactions. A review in Circulation Research describes SIRT1-SIRT7 as NAD+-dependent deacylases, enzymes that remove chemical groups from proteins.
Removing a chemical tag can change how a protein works or interacts with other proteins. Sirtuins are not all alike, so a result for one type cannot stand in for the whole family.
The types also differ in where they are found. A review in Frontiers in Physiology places SIRT3 to 5 in mitochondria, cell structures involved in energy supply, and SIRT6 to 7 mainly in the nucleus, where most cell DNA is held.
NADH is a related form of NAD+. Measuring NAD+ alone does not reveal how much NADH is present or how the two forms balance.
NAD+ is not a receptor that a drug binds to. Its role here is as a coenzyme used in reactions, including those carried out by sirtuins.
A test of NAD+ or NADH gives a snapshot of the amount in a sample. A ratio between the two can describe their balance at that time, but it does not show how quickly either form is made or used.

Mass spectrometry can distinguish NAD+ from NADH by measuring their mass and electrical charge. Other lab tests may estimate one form or both, so results from different test methods may not match exactly.
How samples are prepared matters as much as how they are read. Targeted liquid chromatography-tandem mass spectrometry separates NAD+ and NADH before detection; isotope-labelled internal standards can help account for extraction losses and variation in instrument response. Researchers should state whether they tested whole blood, plasma, or isolated cells, and how samples were quenched and stored. NAD+ and NADH can shift during handling, so a precise instrument reading cannot repair a poorly controlled collection process. Comparisons are strongest when the same sample type, protocol, and calibration are used.
Researchers also study the NAD+ salvage pathway, the process that rebuilds NAD+ from reused parts. Measuring NAMPT, an enzyme involved in this pathway, can show one part of that rebuilding process.
NAD+ is used by more than sirtuins. Poly-ADP-ribose polymerase (PARP) enzymes use it in reactions that affect proteins, while CD38 is an enzyme that uses and breaks down NAD+.
For this reason, a change in NAD+ does not identify which enzyme or pathway caused the change. Studies need separate measures of NAD+ and the process they aim to test.
The amount of a sirtuin protein and its activity are different measures. A sample may contain more of the protein without showing that it is doing more work.
A direct activity test measures how quickly a sirtuin changes a target protein under set lab conditions. It can support a claim about activity in that test, but it does not alone show what happens across a whole body.
Researchers may also measure protein acetylation, the presence of acetyl tags on proteins. A change in these tags may fit with sirtuin action, but other enzymes and processes can also change them.
Tests aimed at one sirtuin help separate its role from the roles of other family members. Controls, or comparison tests, and experiments that block or remove the sirtuin can further test whether it caused the measured result.
Stronger evidence comes from several linked measures. For example, a study can measure NAD+, test the activity of one sirtuin, and then measure a protein that the sirtuin is thought to affect.
An informative design links each claim to a matching readout: quantify NAD+ in the tissue where the proposed effect occurs, test the named sirtuin's activity under stated assay conditions, then examine acetylation of a relevant target alongside that target protein's abundance. If activity rises in a purified-enzyme assay but target-protein acetylation does not change in cells, the evidence supports enzyme capacity in the test tube, not pathway engagement in tissue. Conversely, target acetylation alone is not proof, because other enzymes can alter it. This cross-check helps distinguish a direct mechanism from correlated markers.
The right sample depends on the study question. Blood, muscle, liver, and brain can differ, so a result in one tissue does not establish what is happening in another.

NAD+ can also vary across parts of a cell. A whole-cell measurement may hide a change in the mitochondria or nucleus, where different sirtuins are found.
Study groups need the same sample collection and storage steps. Delays or changes in handling can alter the measured amount of a short-lived molecule.
Timing matters too. Researchers compare samples at matching points after a study intervention or meal because levels and enzyme activity can shift over time.
These limits apply to studies of NAD+ materials as well as to cell samples. The listed NAD+ 1000mg is described as a research-use material, which makes clear that the product itself is not a measure of a study outcome.
Cell studies can test a pathway in a controlled setting. Researchers can change one part of a cell system and measure what follows, but that result alone does not establish an effect in an animal or a person.
Animal studies can track changes across tissues and whole-body functions. Aging, metabolic, heart, and brain studies may measure cell function, blood markers, movement, or memory-related tasks.
Those measures describe the model and test used. An animal result does not by itself show that the same change will occur in people or lead to a health benefit.
Human studies of nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN), which are NAD+ precursors, may measure NAD-related markers in blood or tissue. They may also assess metabolic measures or physical function.
Human studies of NR have reported increases in circulating NAD-related metabolites, and NMN trials have also reported increases in blood NAD+ or related measures. These are target-engagement findings: they show that the measured biomarker changed, not that sirtuin activity rose in muscle, brain, or another tissue. Functional results are less uniform. Studies have examined outcomes such as walking performance, aerobic capacity, and physical function, but a blood-marker increase has not translated consistently into measurable benefit across these endpoints. Trial regimens, follow-up periods, participant groups, sample types, and chosen outcomes vary, so results are more useful when considered endpoint by endpoint than when summarized as an effect on aging.
A change in a lab marker is not the same as a functional change. For example, a higher NAD+ measure alone does not show improved movement, memory, or overall health.
Evidence is easier to judge when each step is measured separately. A change in NAD+ shows a change in that measure; a direct sirtuin test can support a change in activity; and a change in a target protein adds another link.

That chain still needs tests of cause. Raising NAD+ can affect enzymes and pathways beyond sirtuins, so a study needs to test whether the sirtuin itself is required for the result.
Findings that connect pathway measures with relevant functional outcomes in people support a stronger conclusion than findings seen only in cells or animals. The result still applies to the people, measures, and study conditions that were tested.
Changes in NAD+ or sirtuin-related markers do not prove longer life. That claim requires studies that directly measure lifespan.
NAD+ and sirtuin studies measure separate steps, from molecule levels to enzyme activity, protein changes, and function. The clearest conclusions come when studies link those steps in the same tissue and model, while testing whether a particular sirtuin caused the effect.